Italia markets closed

Oxurion NV (0G99.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,4350+0,0250 (+6,10%)
Alla chiusura: 04:22PM BST
Schermo intero
Chiusura precedente0,4100
Aperto0,4200
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,4080 - 0,4350
Intervallo di 52 settimane0,4080 - 0,4350
Volume676
Media VolumeN/D
Capitalizzazione16,873M
Beta (5 anni mensile)1,09
Rapporto PE (ttm)N/D
EPS (ttm)-0,7590
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Oxurion Announces Two Presentations at The Macula Society 45th Annual Meeting

    Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two presentations were delivered at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany. The Macula Society presentations are available under Conferences and Events within the Investors section of the Company’s webs

  • GlobeNewswire

    Oxurion Announces Preclinical Presentation on THR-149 at KININ2022

    Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in patients with retinal disorders including diabetic macular edema, today delivered a preclinical presentation evaluating the pharmacokinetic properties of THR-149 at KININ2022, held in Annecy, France, June 5-8, 2022. The KININ2022 presentation is available under Conferences and Events within the Invest

  • GlobeNewswire

    Oxurion Announces Two Upcoming Presentations at The Macula Society 45th Annual Meeting

    Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two abstracts will be presented at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of diabeti